We studied a 5-year-old girl presenting with a markedly prolonged bleeding time. Her platelets were refractory to collagen stimulation, but the response to other agonists was normal. There were no coagulation abnormalities as measured by standard tests. Two-dimensional electrophoresis showed no abnormalities of the patient's platelet membrane glycoproteins. When the patient's plasma or purified plasma IgG was mixed with normal platelets, collagen-induced platelet aggregation was blocked. Western blotting showed the presence of an antibody in the patient's plasma directed against a protein of molecular weight 85 to 90 Kd under both UMEROUS MEMBRANE proteins have been pro-N posed as the collagen receptor on blood platelets.
reducing and nonreducing conditions. This protein comigrated with glycoprotein (GP) IV immunoprecipitated by OKM5 from '251-labeled platelets. Immunoprecipitation of '%labeled normal platelet glycoproteins with the patient's lgGs also yielded an 85-to 90-Kd protein that migrated on the diagonal following nonreduced/reduced two-dimensional sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Despite similarities in electrophoretic behavior, the antigen was not demonstrated to be GPIV, since purified GPIV was not recognized by the antibody. 0 1992 by The American Society of Hematology.
CASEREPORT
A 5-year-old girl presented with a history of recurrent ecchymoses and epistaxis from birth onwards. She also had prolonged bleeding after subcutaneous vaccination. Two years earlier she had a severe upper gastrointestinal hemorrhage. Template bleeding time was prolonged to 13 minutes (normal range, 3 to 8 minutes) and the diagnosis of a platelet dysfunction was made. She had been treated with a transfusion of 500 mL of whole blood following the hematemesis.
At presentation in our center, the subject had several ecchymoses of different durations on the cheeks, forehead, abdomen, and legs. Platelet counts were in the normal range (310.109/L in whole blood, 447.109/L in platelet-rich plasma [PRP] ). No abnormalities were seen in the coagulation tests (prothrombin and thrombin time, activated partial thromboplastin time, levels of fibrinogen, factor VI11 and XIII, von Willebrand factor). Platelet aggregations were normal, including the ones induced by NaF, a direct stimulator of guanosine triphosphate (GTP)-binding proteins,14 except for a subnormal collagen-induced aggregation (Fig 1) . Platelet aggregation studies and evaluations of platelet and plasma samples were performed 17 and 24 months after the blood transfusion. The subject still has frequent spontaneous ecchymoses and nose-bleeds, but otherwise is in good health.
MATERIALS AND METHODS

Platelet Aggregation Studies
PRP and platelet-poor plasma (PPP) were obtained following centrifugation, at 150 x g and 1,200 x g for 10 minutes, respectively, of blood collected on 1/10 vol 3.15% trisodium citrate.
Platelet aggregation was studied with the optical method using an Elvi 840 dual-channel aggregometer (Elvi Logos, Milano, Italy). Aggregations were induced with adenosine diphosphate (ADP), adrenaline, arachidonic acid (all from Sigma Chemical, St Louis, MO), ristocetin (Lundbeck, Copenhagen, Denmark), NaF (Baker Chemical, Philipsburg, NJ), or collagen from equine tendons (Hormon Chemie, Munich, Germany).
In some cases, platelets from the patient or from normal volunteers were prepared by gel filtration using Sepharose 2B. To 200 pL of these, 50 pL of either normal or patient plasma was added and incubated at room temperature for different times, after which collagen-mediated aggregation was induced.
In another series of experiments, purified IgGs (0.277 mg/mL) were incubated with normal gel-filtered platelets in a 115 dilution of normal plasma, before the aggregation was induced. Patient and control IgG were prepared by diluting the plasma 1/6 with 0.1 mol/L Tris-HC1, pH 8.1, of which 6 mL was applied on a 10-mL protein A-Sepharose column (Pharmacia, Uppsala, Sweden) and eluted with 0.1 molIL citrate buffer, pH 5. dialyzed against phosphate-buffered saline (PBS) and stored at -20°C.
Ident8cation of Platelet Proteins
Platelets from the patient and normal donors were gel-filtered as above, centrifuged at 8OOg for 10 minutes, and resuspended at a final concentration of 1.5 X lo9 platelets/mL in PBS containing 200 U/mL Trasylol (Bayer, Brussels, Belgium) and 4 mmol/L EDTA. Surface glycoproteins of a 50-pL platelet suspension were radioiodinated using Enzymobead Reagent (Biorad, Richmond, CA), 0.5 mCi Na'=I (Amersham, Amersham, UK), and 1% ~-D-ghCOSe during a 10-minute incubation period. After washing platelets and beads with PBS by two consecutive centrifugation (12,00% 3 minutes) and resuspension cycles, the platelet proteins were solubilized with PBS containing 1% Triton X-100. The supernatant was collected after another centrifugation step, and proteins were separated on two-dimensional nonreduced/reduced sodium dodecy1 sulfate (SDS)-7.5% polyacrylamide gel electrophoresis (PAGE), which finally were submitted to autoradiography using hyperfilm-MD (Amersham).
Identification of the Platelet Antigen
Proteins from gel-filtered platelets were separated by one-dimensional 7.5% SDS-PAGE and blotted on nitrocellulose (Schleicher & Schuell, Dassel, Germany) using semidry electroblotting. Following transfer, the filters were blocked with 5% bovine serum albumin (BSA), incubated with undiluted normal or patient's plasma, or patient's IgG, purified by protein A-Sepharose affinity chromatography. This was followed by an incubation with either protein A (Biorad) or goat anti-human IgG (Nordic Immunology, Tilburg, The Netherlands), both coupled to horseradish peroxidase (HRP). Color development was performed Westem blotting. with 0.018% H,O, and HRP-color development reagent, containing 4-chloro-1-naphtol (Biorad) according to the manufacturer's instructions. Prestained proteins (Biorad) were used as molecular weight standards.
One hundred fifty microliters of '=I-labeled Triton X-100 platelet lysate (as above) was incubated with either 1 mL of patient's plasma or 100 pL of 100 pg/mL OKM5 (Ortho Diagnostic Systems, Raritan, NJ) at 4°C for 20 hours, after which 200 pL protein A-Sepharose beads (Pharmacia) was added and incubated for another 2 hours at room temperature. To reduce nonspecific binding, the protein A-Sepharose beads had been preincubated with nonlabeled Triton X-100 platelet lysate for 2 hours at room temperature, after which they had been washed twice with 1 mL PBS, 0.1% Triton X-100. Following binding of the immune complexes to the protein A-Sepharose, they were again washed twice and 30 pL Laemmli-buffer, nonreducing, was finally added to the bead-pellet. After boiling for 2 minutes, the Sepharose was spun down once more, and the supernatant was collected and analyzed by one-or two-dimensional 7.5% SDS-PAGE, followed by autoradiography.
Purified GPIV used was given to us by Dr Tandon and Dr Jamieson (Rockville, MD) or was purified as described by the same investigators.'' Purity was checked with SDS-PAGE, followed by silver staining. The identity of the purified protein was further established in a Western blot analysis using a murine anti-GPIV monoclonal antibody Mo-91 (a generous gift from Dr Tandon and Dr JamiePurified GPIV was used as antigen for the patient's antibody in Western blots, as above, or in an enzyme-linked immunosorbent assay (ELISA) set-up in which 200 pL of 5 pg/mL purified GPIV was coated onto microtiter plates overnight at 4°C. Following three washes with PBS-0.002% Tween-80, control or patient plasma, protein A-Sepharose purified IgGs or Fab fragments were put on the plates in serial dilutions. Following a 2-hour incubation period, plates were washed again and incubated with goat anti-human IgG (Sigma) coupled to HRP for another 2 hours. After a final wash, color development was performed using 0-phenylenediamine (Fluka, Buchs, Switzerland) and 0.003% H,O,; the reaction was terminated with an equal volume of 4 mol/L H,SO, and light absorbance was measured at 492 nm. Fab fragments were prepared by digesting purified IgGs with 0.1 mg/mL papaine in 0.4 mol/L phosphate buffer, pH 7.4, 4 mmol/L EDTA, and 20 mmol/L L-cysteine over 72 hours at 37°C and further separated from Fc fragments on protein A-Sepharose. Purity was checked by SDS-PAGE.
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RESULTS
Platelet Aggregation Tests
Normal gel-filtered platelets incubated for various times with $4 vol plasma from the patient lost their response to collagen as a function of preincubation time, whereas simultaneous incubation with normal plasma did not change the aggregation response (Fig 2) .
Preincubation of patient IgG, affinity-purified on protein A-Sepharose, with normal platelets also inhibited their aggregation by collagen. Normal human immunoglobulins were without effect (Fig 3) . On the other hand, mixing normal plasma with gel-filtered platelets from the patient did not restore their responsiveness to collagen.
For 
Platelet Proteins and Antigen
Two-dimensional analysis of the patient's platelet proteins in parallel with a normal sample did not show any obvious deficiencies or changes in the '2SI-labeled glycoprotein pattern (Fig 4) . In addition, an anti-GPIV antibody indicated the presence of GPIV in a Western blot of the patient's platelet proteins.
Western blotting of normal human platelet proteins developed with either the patient's plasma or her purified IgG, followed by development with protein A or goat anti-human IgG coupled to HRP, showed a strongly colored band at approximately 88 Kd, which did not change on reduction of the disulfide bonds. This band furthermore comigrated with 'L'I-GPIV immunoprecipitated from a 'sI-labeled platelet lysate by OKM5 (Fig 5) . However, the immunoprecipitated GPIV did not give a positive signal when developed in a Western blot with the patient's plasma. The immunoprecipitate of a similar platelet lysate with the patient's plasma and protein A-Sepharose beads, ran on a two-dimensional gel electrophoresis on the diagonal with a molecular weight of approximately 88 Kd (Fig 6) .
GPIV, purified according to the protocol of Tandon et al," yields a 95% to 99% pure 88-Kd protein (Fig 7) , which is recognized by Mo-91, indicating its identity with GPIV. Since at this point a new plasma sample from the patient failed to detect a protein in Western blots of normal or patient platelets or of purified GPIV, despite consistent absence of collagen-induced platelet aggregation, an ELISA system was set up to detect antibody binding to GPIV. Whereas Mo-91 gave a dose-dependent signal in the ELISA (Fig 7) , the patient's plasma, purified IgG, or Fab fragments did not give a signal substantially different from the one obtained with corresponding samples from normal volunteers. Furthermore, a GPIV-specific monoclonal antibody-based antigen-capture technique (h4AIPAI6) also did not show the presence of an anti-GPIV antibody (C. Muller-Eckhardt, personal communication).
DISCUSSION
We report here on a patient suffering from a hemorrhagic disorder characterized by severe bruising from birth onwards, a prolongcd blccdiiig iimc, uiid an isolated defect in the responsiveness of the platelets to collagen.
Thc patient studied here differs from earlier cases with similar features'.'.''.'2 in which a glycoprotein deficiency was found. The patient's platelets presented a normal pattern of glycoprotein distribution as judged from two-dimensional electrophoresis.
For Mixing cxpcrimcnts, on thc othcr hand, showed the prcscncc of an inhibitor of collagen-induced platclct aggrcgation in the paticnt's plasma, which was still prcscnt in purificd paticnt IgG. Howcvcr, mixing paticnt's platclcts with normal plasma failcd to rcstorc thcir rcsponsc, perhaps due to a persistent occupancy of thc platclct rcccptor by IgG or to a dcfcctivc rcceptor.
Wc previously'" dcscribcd a patient with an autoantibody dircctcd against GPIa, which also inhibited platelct activation by collagen. The inhibitory antibody in the plasma of the present paticnt is not directed against GPIa, which has GPIV, which has bccn identificd as a collagen receptor on platelets," has a molecular wcight of 88 Kd, which also does not change on rcduction. Dcspitc the fact that the antigen comigrates with GPIV, no evidence could be obtained to indicate thcir identity: immunoprecipitated or purified GPIV was not rccognized in Western blots, nor did purified GPIV serve as an antigen in an ELISA. A GPIVspecific MAIPAl6 also failed to detect an anti-GPIV antibody in thc patient's plasma. Also, based on functional evidence, the antibody studied here seems to be directed against a glycoprotein othcr than GPIV, since recently a number of healthy blood donors havc been described with platelets lacking detcctablc GPIV."."' These donors did not havc bleeding problems and their platelets did respond normally to collagen,'" except for a reduced early adhesion'" and a dcficicnt aggregation rcsponsc to collagen type V only."
We therefore conclude that the plasma of a patient with sevcre bruising, prolonged bleeding time, and an isolated defect in the rcsponsivcncss of thc platclcts towards collagen contains an IgG that inhibits normal platelet reaction towards collagen. It is furthcrmorc dirccted against an 85-to 90-Kd platclet surface protein, which, howcvcr, is distinct from GPIV. On the othcr hand, the bleeding tendency was evident from birth onwards, and the paticnt's platelets, when rcsuspcndcd in normal plasma, still did not respond to collagcn; apparently, thc antibody titer seemed to decline (based on decreasing signals in Wcstem blotting) as a function of thc intcrval following reccipt of a blood transfusion. It defective collagen receptor on the patient's platelets, and that the antibodies resulted from sensitization following blood transfusion. Finally, since the glycoprotein pattern of the patient's platelets was indistinguishable from the one of a normal control, this implies that either a minor membrane protein is absent or that a functionally inactive collagen receptor is present on the patient's platelets.
Several platelet glycoproteins have been proposed to be collagen-receptors; however, only for three of them has evidence been obtained for a physiological function: patients with either a deficiency of or a neutralizing antibody against GPIa/IIa,1-3.'o GPVI," or the 85-to 90-Kd protein described here have bleeding problems ranging from mild to severe. Other putative collagen receptors on platelets may be less relevant for the in vivo situation.
The finding that defective platelet-collagen interaction with normal platelet reaction towards other agonists may result in bleeding problems is an additional indication for the importance of this pathway in the maintenance of normal hemostasis. Adhesion of platelets to collagen at sites of damaged endothelium thus seems to play a crucial role in the initiation of hemostasis.
Finally, a defective interaction of one of several platelet receptors with collagen is sufficient to have a profound effect, implying that collagen has to interact with all of them to provoke a full platelet activation." Whether this multiple interaction scheme involves a sequential or a simultaneous binding of collagen to its various receptors is at present unclear.
